SNY : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  3. Bull of the Day: ViroPharma (VPHM) - Bull of the Day

    October 23, 2013
    Bull of the Day: ViroPharma (VPHM) - Bull of the Day
  4. Novo Nordisk Getting Its Trial By Fire

    August 8, 2013
    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  5. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  6. Peregrine's 4Q Loss In Line - Analyst Blog

    July 15, 2013
    Peregrine Pharma reported a net loss of 6 cents per share in the fourth quarter of fiscal 2013.
  7. Astellas Launches Xtandi in the UK - Analyst Blog

    July 12, 2013
    Astellas Pharma announced the launch of its prostate cancer drug, Xtandi, in the UK
  8. BMY/Pfizer Seek to Expand Eliquis Label - Analyst Blog

    July 12, 2013
    Bristol-Myers Squibb Company and partner Pfizer announced that their supplemental New Drug Application for Eliquis has been ...
  9. Alnylam Up to Positive Data - Analyst Blog

    July 12, 2013
    Alnylam announced positive top-line results from a phase I study on ALN-TTRsc.
  10. BioMarin Stays Neutral - Analyst Blog

    July 8, 2013
    We recently maintained our Neutral recommendation on BioMarin Pharma.
  11. Glaxo Initiates Phase III Study - Analyst Blog

    July 8, 2013
    GlaxoSmithKline has initiated a phase III study on a subcutaneous formulation of Arzerra
  12. Isis Achieves New 52-Week High - Analyst Blog

    July 8, 2013
    Share price of Isis Pharmaceuticals reached a new 52-week high on Jul 5, 2013.
  13. CRL for Merck's Suvorexant - Analyst Blog

    July 2, 2013
    The FDA issued a complete response letter (CRL) for Merck's insomnia candidate, suvorexant.
  14. Taking The Contrarian Approach With European Equities

    July 2, 2013
    Investors continue to shun European equities due to the regions debt issues and economic problems. However, that’s a real ...
  15. Positive Data on Alnylam's Candidate - Analyst Blog

    July 1, 2013
    Alnylam announced positive interim results from a phase II study on ALN-TTR02.
  16. Evenly Poised on Regeneron - Analyst Blog

    June 25, 2013
    We retained our Neutral recommendation on Regeneron Pharma.
  17. New Data on Novo Nordisk's Tresiba - Analyst Blog

    June 24, 2013
    Novo Nordisk presented new data on its type II diabetes drug, Tresiba (degludec), from a one-year extension study (BEGIN ...
  18. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  19. Label Updates for Lilly/Boehringer Diabetes Drugs - Analyst Blog

    June 21, 2013
    The companies said that labels for Tradjenta and Jentadueto will contain additional information about the risk of pancreatitis.
  20. Good News for InterMune - Analyst Blog

    June 17, 2013
    The pricing and reimbursement conditions for InterMune's Esbriet was approved in Italy.
  21. Top-Performing Dividend Payers in Health Care with the Most Upside ...

    June 8, 2013
    It is not unusual for stocks on a tear to overrun their mean price targets, which is a signal of how far analysts on average ...
  22. FDA Panel Positive on GSK's Avandia - Analyst Blog

    June 7, 2013
    The FDA panel recently voted in favor of easing safety restrictions related to Glaxo's Avandia.
  23. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  24. Hospira Beats by a Penny - Analyst Blog

    February 14, 2013
    Hospira Inc.'s (HSP) fourth quarter 2012 earnings (excluding special items) of 55 cents per share beat the Zacks Consensus ...
  25. Sanofi Shows Interest in Regeneron - Analyst Blog

    February 12, 2013
    Regeneron Pharmaceuticals, Inc. (REGN) recently announced that it has received a notification under the Hart-Scott-Rodino ...
  26. Cardiome Selects Quintiles - Analyst Blog

    February 12, 2013
    Cardiome Pharma Corp. (CRME) recently selected privately-held Quintiles for providing lifecycle safety and global regulatory ...
  27. Pipeline Progresses at Shire - Analyst Blog

    February 12, 2013
    Shire plc (SHPG) recently announced that the company has initiated a phase III study to evaluate the efficacy and safety ...
  28. Acorda Presents Encouraging Data - Analyst Blog

    February 11, 2013
    Acorda Therapeutics, Inc. (ACOR) recently announced that data from preclinical studies evaluating glial growth factor 2 (GGF2) ...
  29. Novo Nordisk Suffers Setback - Analyst Blog

    February 11, 2013
    Novo Nordisk (NVO) recently faced a setback when the US Food and Drug Administration (FDA) declined to approve its diabetes ...
  30. Myriad Tops Estimates; Tweaks View - Analyst Blog

    February 8, 2013
    Myriad Genetics Inc. (MYGN) reported EPS of 42 cents in the second quarter of fiscal 2013, representing a beat of 10.5% over ...
  31. Teva Misses, Hikes Dividend - Analyst Blog

    February 8, 2013
    Teva Pharmaceutical Industries (TEVA) reported fourth quarter earnings of $1.32 per American Depositary Share (ADS), a penny ...
  32. Sanofi's Diabetes Drug Gets EU Nod - Analyst Blog

    February 7, 2013
    Recently, Sanofi (SNY) received encouraging news with the European Commission (EC) approving its diabetes candidate, Lyxumia ...
  33. Glaxo Strengthens Indian Presence - Analyst Blog

    February 6, 2013
    GlaxoSmithKline (GSK) recently increased its holding in its consumer healthcare subsidiary in India, GlaxoSmithKline Consumer ...
  34. Bayer, J&J Collaborate with Portola - Analyst Blog

    February 6, 2013
    Bayer's (BAYRY) Healthcare unit and Johnson & Johnson's (JNJ) Janssen Pharmaceuticals recently collaborated with Portola ...
  35. SNY/REGN's Zaltrap Approved in EU - Analyst Blog

    February 6, 2013
    Recently Sanofi (SNY) and partner Regeneron Pharmaceuticals Inc. (REGN) received encouraging news with the European Commission ...
  36. AGN Earnings Miss but Guidance Tops - Analyst Blog

    February 5, 2013
    Allergan, Inc. (AGN) reported fourth quarter 2012 earnings of $1.15 per share, missing the Zacks Consensus Estimate of $1.19 ...
  37. Pipeline Progress at Glaxo - Analyst Blog

    February 4, 2013
    Recently, GlaxoSmithKline (GSK) announced the initiation of a phase III study (COMBI-AD) to evaluate its oncology candidate ...
  38. Strong 2012 Results at Novo Nordisk - Analyst Blog

    February 1, 2013
    Novo Nordisk (NVO) reported fourth quarter 2012 earnings of $1.83 per American Depository Receipt (ADR), up 21.2% from the ...
  39. Merck Beats, Issues Outlook - Analyst Blog

    February 1, 2013
    Merck & Co. (MRK) reported fourth quarter 2012 earnings per share (excluding special items) of 83 cents, a couple of cents ...
  40. Favorable Ruling for Allergan - Analyst Blog

    January 29, 2013
    Allergan (AGN) received some positive news when the US Court of Appeals for the Federal Circuit ruled in its favor and found ...
  41. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  42. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  43. Eli Lilly Beats Expectations - Analyst Blog

    January 29, 2013
    Eli Lilly & Company (LLY) reported fourth quarter 2012 adjusted earnings per share of 85 cents, well above the Zacks Consensus ...
  44. Pfizer Tops, Guides In Line - Analyst Blog

    January 29, 2013
    Pfizer Inc. (PFE) posted fourth quarter earnings of 47 cents per share, 3 cents above the Zacks Consensus Estimate but 4% ...
  45. Theravance Winds up Public Offering - Analyst Blog

    January 28, 2013
    Theravance, Inc. (THRX) recently announced that it has completed its public offering of $287.5 million convertible subordinated ...
  46. Earnings Miss for Biogen - Analyst Blog

    January 28, 2013
    Biogen Idec (BIIB) reported fourth quarter earnings per share of $1.40, missing the Zacks Consensus Estimate of $1.46 and ...
  47. Earnings Beat at Bristol-Myers - Analyst Blog

    January 24, 2013
    Bristol-Myers Squibb Company's (BMY) fourth quarter 2012 earnings (excluding special items) of 47 cents per share were ahead ...
  48. Allergan to Buy MAP Pharmaceuticals - Analyst Blog

    January 23, 2013
    In a bid to strengthen its position in the neurology and migraine specialty fields, Allergan, Inc. (AGN) recently inked a ...
  49. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  50. J&J Beats on EPS but Guidance Lags - Analyst Blog

    January 22, 2013
    Johnson & Johnson's (JNJ) fourth quarter 2012 earnings (excluding special items) of $1.19 per share were a couple of cents ...
  51. Theravance to Offer Notes - Analyst Blog

    January 17, 2013
    Theravance, Inc. (THRX) announced recently that it intends to offer $250 million convertible subordinated notes, due in 2 ...
  52. Oscar Nominations Are Out: Which Studio Benefits Most?

    January 16, 2013
    The 2013 Oscar nominations were announced January 11. Who wins financially from the film industry's annual pat on the back?
  53. Canadian Approval for BMY's Drug - Analyst Blog

    January 16, 2013
    Good news flowed in at Bristol-Myers Squibb (BMY) from Canada when Health Canada, the federal department responsible for ...
  54. Glaxo/THRX Seek European Approval - Analyst Blog

    January 10, 2013
    GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced the submission of a marketing application to the European ...
  55. Pipeline Update from Alnylam - Analyst Blog

    January 8, 2013
    Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its key "Alnylam ...
  56. Bayer Submits Regorafenib in Japan - Analyst Blog

    December 28, 2012
    Bayer Yakuhin Ltd., the Japanese subsidiary of Bayer AG (BAYRY), submitted a marketing authorization application for regorafenib ...
  57. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  58. Sanofi SA and More Big Movers in Healthcare on December 28, 2 ...

    December 28, 2012
    The market is currently down, with the Nasdaq decreasing 0.3%, the S&P 500 declining 0.5% and the Dow falling 0.5%. The healthcare ...
  59. FDA Approves Aegerion's Juxtapid - Analyst Blog

    December 26, 2012
    The US Food and Drug Administration (FDA) recently approved Aegerion Pharmaceuticals' (AEGR) Juxtapid (lomitapide) capsules. ...
  60. Back to Neutral on Bayer - Analyst Blog

    December 26, 2012
    We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive news that led to our previous ...
  61. Myriad Alleviates to Outperform - Analyst Blog

    December 21, 2012
    Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), ...
  62. NVO Progresses with Pipeline - Analyst Blog

    December 20, 2012
    Novo Nordisk (NVO) recently completed a phase IIIa study on IDegLira, which is a combination of Tresiba (insulin degludec) ...
  63. Isis Pharma, AstraZeneca Ink Deal - Analyst Blog

    December 14, 2012
    Isis Pharmaceuticals Inc. (ISIS) and AstraZeneca (AZN) recently announced that they have entered into an agreement to discover ...
  64. Sanofi Presents Positive Results - Analyst Blog

    December 13, 2012
    Sanofi (SNY) recently announced positive results from a phase II trial evaluating the efficacy of its hematology candidate, ...
  65. BMY/ABT Present Oncology Data - Analyst Blog

    December 12, 2012
    Bristol-Myers Squibb Company (BMY) and partner Abbott Laboratories (ABT) recently presented data on their oncology candidate ...
  66. Novartis Presents Jakavi Data - Analyst Blog

    December 12, 2012
    Swiss pharmaceutical giant Novartis (NVS) recently presented data from two phase III trials (COMFORT-I and COMFORT-II) on ...
  67. NVS Provides Tasigna Study Data - Analyst Blog

    December 11, 2012
    Swiss pharmaceutical giant Novartis (NVS) recently presented data from two phase III studies comparing Tasigna (nilotinib) ...
  68. Merck's Alzheimer's Drug Progresses - Analyst Blog

    December 10, 2012
    Merck (MRK) recently moved its Alzheimer's disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will ...
  69. Data from Roche's Perjeta Study - Analyst Blog

    December 10, 2012
    Roche Holding (RHHBY) recently announced survival data from its phase III CLEOPATRA study on Perjeta (pertuzumab). Data ...
  70. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  71. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  72. Another Generic from Dr. Reddy's - Analyst Blog

    November 23, 2012
    Dr. Reddy's Laboratories (RDY) recently launched its generic version of Pfizer's (PFE) pulmonary arterial hypertension (PAH) ...
  73. CHMP Positive on Sanofi's Lyxumia - Analyst Blog

    November 21, 2012
    Sanofi (SNY) recently announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...
  74. MannKind Inks Deal with Colby - Analyst Blog

    November 15, 2012
    MannKind Corporation (MNKD) recently signed a license agreement with Colby Pharmaceutical Company granting the latter exclusive ...
  75. Stock Market News for November 13, 2012 - Market News

    November 13, 2012
    Apprehension about this week's "fiscal cliff" discussion between top U.S. leaders and President Barack Obama led to benchmarks ...
  76. Revenues Decline at Alnylam - Analyst Blog

    November 7, 2012
    Alnylam Pharmaceuticals Inc.'s (ALNY) third quarter 2012 net loss of 38 cents per share was wider than the year-ago loss ...
  77. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  78. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  79. Earnings Beat for Teva - Analyst Blog

    November 2, 2012
    Teva Pharmaceutical Industries' (TEVA) third quarter earnings of $1.28 per American Depositary Share (ADS) were 3 cents above ...
  80. Watson Beats, Revises Outlook - Analyst Blog

    November 1, 2012
    Watson Pharmaceuticals Inc.'s (WPI) third quarter 2012 earnings (excluding special items) of $1.35 per share surpassed the ...
  81. Solid Quarter at Dr. Reddy's - Analyst Blog

    October 31, 2012
    Dr. Reddy's Laboratories (RDY) reported second quarter fiscal 2013 earnings per American Depositary Share (ADS) of 50 cents, ...
  82. Biogen Beats, Raises View Again - Analyst Blog

    October 25, 2012
    Biogen Idec (BIIB) reported third quarter earnings per share of $1.90, well above the Zacks Consensus Estimate of $1.61 and ...
  83. Generic Plavix Hurts Bristol-Myers - Analyst Blog

    October 24, 2012
    Bristol-Myers Squibb Company's (BMY) second quarter 2012 earnings (excluding special items) of 48 cents per share fell short ...
  84. FDA Label Expansion for Abraxane - Analyst Blog

    October 23, 2012
    Celgene Corporation (CELG) announced that it has received approval from the US Food and Drug Administration (FDA) for a label ...
  85. Back to Neutral on Regeneron - Analyst Blog

    October 11, 2012
    We are reverting to a Neutral recommendation on Regeneron Pharmaceuticals (REGN) as we believe that all the positive news ...
  86. Bayer's Stivarga Gains Approval - Analyst Blog

    September 28, 2012
    The HealthCare unit of Bayer (BAYRY) recently announced that the US Food and Drug Administration (FDA) has cleared its oncology ...
  87. Sanofi SA Among Healthcare's Biggest Movers on September 28, ...

    September 28, 2012
    On a bad day for the market, the Nasdaq has fallen 0.8%, the S&P 500 is trading down 0.7% and the Dow has declined 0.7%. ...
  88. CHMP in Favor of Lilly's Cialis - Analyst Blog

    September 25, 2012
    Eli Lilly and Company's (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products ...
  89. New Data on Merck's Insomnia Drug - Analyst Blog

    September 17, 2012
    Merck & Co. (MRK) recently presented new data on its insomnia candidate, suvorexant, at the 21st Congress of the European ...
  90. Sanofi SA Among Healthcare's Biggest Movers on September 11, ...

    September 11, 2012
    The Nasdaq has increased 0.3%, the S&P 500 has risen 0.6% and the Dow has moved up 0.7% on a good day for the market so far. ...
  91. Still Neutral on Bristol-Myers - Analyst Blog

    September 6, 2012
    We are maintaining our Neutral recommendation on Bristol-Myers Squibb Company (BMY) with a target price of $35.00. The stock ...
  92. Sanofi's Lemtrada US Filing Update - Analyst Blog

    August 28, 2012
    Sanofi's (SNY) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has issued a refuse-to-file ...
  93. Bad News for Bristol-Myers - Analyst Blog

    August 27, 2012
    Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback when it announced the discontinuation of the development ...
  94. Alnylam/Isis's Regulus to Go Public - Analyst Blog

    August 22, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  95. Watson Pharma Sues FDA - Analyst Blog

    August 17, 2012
    Watson Pharmaceuticals Inc. (WPI) recently announced the filing of a lawsuit against the US Food and Drug Administration ...
  96. Biogen Inks Deal with Regulus - Analyst Blog

    August 16, 2012
    Regulus Therapeutics Inc. and Biogen Idec (BIIB) recently entered into a deal to identify microRNAs (micro-RiboNucleic Acids) ...
  97. Decision Date for Medivation Drug - Analyst Blog

    August 7, 2012
    Medivation, Inc. (MDVN) and Astellas Pharma Inc. recently announced that the US Food and Drug Administration (FDA) will deliver ...
  98. Pipeline Setback at Bristol-Myers - Analyst Blog

    August 3, 2012
    Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback when it voluntarily decided to halt a phase II study ...
  99. Teva Misses, Maintains View - Analyst Blog

    August 3, 2012
    Teva Pharmaceutical Industries' (TEVA) second quarter earnings of $1.28 per American Depositary Share (ADS) were a penny ...
  100. FDA Accepts Medivation's NDA - Analyst Blog

    July 27, 2012
    Medivation Inc. (MDVN) and its partner Astellas Pharma Inc. recently reported that the New Drug Application (NDA) for their ...
  101. Earnings Beat for Novartis - Analyst Blog

    July 20, 2012
    Swiss pharmaceutical giant Novartis (NVS) reported second quarter 2012 earnings per share of $1.12, down 1% from the year-ago ...
  102. Dr. Reddy's Launches Generic Lipitor - Analyst Blog

    July 19, 2012
    Yet another generic version of Pfizer's (PFE) cholesterol drug, Lipitor (atorvastatin calcium), entered the market recently ...
  103. Pipeline Progresses at Nymox - Analyst Blog

    July 12, 2012
    Nymox Pharmaceutical Corporation (NYMX) recently announced that it has completed enrollment of benign prostatic hyperplasia ...
  104. Isis Pharma Stays Neutral - Analyst Blog

    July 11, 2012
    We recently reiterated our Neutral recommendation on Isis Pharmaceuticals (ISIS), which carries a Zacks #3 Rank (short-term ...
  105. Merck KGaA's Erbitux Disappoints - Analyst Blog

    July 10, 2012
    Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND trial, ...
  106. BMY, Emory University Join Forces - Analyst Blog

    June 21, 2012
    Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Emory University for the development of the former's pipeline ...
  107. BMY Presents Data on Sprycel - Analyst Blog

    June 18, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Otsuka Pharmaceutical Europe Ltd. presented six-year follow-up data ...
  108. Sanofi Submits Lemtrada Application - Analyst Blog

    June 14, 2012
    Sanofi's (SNY) subsidiary, Genzyme, recently announced that it has filed marketing applications for Lemtrada (alemtuzumab) ...
  109. Bristol-Myers Shares Positive Data - Analyst Blog

    June 11, 2012
    Recently, Bristol-Myers Squibb (BMY) and partner AstraZeneca (AZN) presented encouraging data from a phase III study (n=447) ...
  110. BMY Presents Positive Data - Analyst Blog

    June 6, 2012
    Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated ...
  111. The Trend In Rising Cancer Incidences

    June 5, 2012
    As the world continues to modernize and grow, global cancer incidences are expected to increase exponentially and pharmaceutical ...
  112. Look Beyond the Usual Dividend Suspects

    May 15, 2012
    The rush to dividend stocks has left some sectors overvalued, and in most cases, investors can do as well or better with ...
  113. Glaxo Plays Hardball With Human Genome Sciences

    April 24, 2012
    When the pharmaceutical giant GlaxoSmithKline stepped up to the plate with a $13 a share offer for Human Genome Sciences, ...
  114. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  115. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  116. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  117. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  118. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  119. Four Drug Stocks To Watch On Thursday

    July 27, 2011
    Here are four drug stocks investors should watch heading into the second-half of the week.
  120. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  121. Vical Gets Some Validation

    July 19, 2011
    Vical gets a small victory with a partnership for its CMV drug.
  122. Transcept Pharmaceuticals Bulls Get Rude Awakening

    July 15, 2011
    Transcept gets a major setback, but it may not be doomed.
  123. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  124. Lilly Will Pay Investors For Patience

    April 20, 2011
    Lilly isn't dynamic, but the value is there.
  125. Buffett Defends These Stocks As Undervalued

    April 1, 2011
    These stocks allow you to invest in some excellent companies, at a wider discount to intrinsic value than what Berkshire ...
  126. Novavax Gets A Booster Shot From The Government

    March 1, 2011
    Novavax gets a sizable contract from the government that will largely fund its remaining clinical trials for flu vaccines.
  127. The Numbers Behind The Recent Mergers

    February 10, 2011
    By the numbers, it's still up in the air as to whether the most recent wave of mergers & acquisitions were worth the price.
  128. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  129. A Look Back At Biotech

    December 28, 2010
    Big biotechs had a mixed year, with concerns about R&D costs and product sales. The stocks may have seen the worst of it, ...
  130. Has Ingenico Done VeriFone A Favor?

    December 23, 2010
    By rebuffing Danaher, Ingencio may be helping VeriFone.
  131. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  132. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  133. Can New Leadership Rejuvenate Big Pharma?

    December 8, 2010
    Will another new drug company CEO make a difference in a stagnating industry?
  134. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  135. Trick Or Treat For Biodel?

    October 21, 2010
    Will Biodel's upcoming PDUFA date give investors a treat or just leave a sour taste?
  136. Roche Needs A Shot Of Adrenalin

    October 18, 2010
    Roche has a lot of great value characteristics, but value will wither in the absence of growth.
  137. Potential Takeout Targets

    October 1, 2010
    While there is no secret formula for identifying the next possible takeover targets, you can often get some worthwhile ideas ...
  138. Lab Corp And Genzyme Find Some Common Ground

    September 14, 2010
    Genzyme and Lab Corp. forge a rare win-win deal in the lab space.
  139. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  140. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  141. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  142. Biosimilars - The Next Generic Honeypot

    August 10, 2010
    With the first biosimilar approval in over a decade, a major new market for generics could be on the horizon
  143. 3 Hearty Healthcare Investments

    August 6, 2010
    Should the broad market find its legs, look for these issues to outperform.
  144. Profit From Teva's Travails

    July 29, 2010
    Wall Street is giving investors the chance to purchase a top-tier generics company at a discount price.
  145. An Unsurprising Increase In Biotech Acquisitions

    July 28, 2010
    The Sanofi/Genzyme combination isn't the only biotech M&A activity on the radar.
  146. Cancer Vaccines Continue To Show Promise

    July 7, 2010
    Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
  147. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount.
  148. 3 Healthy Healthcare Stocks

    April 6, 2010
    Strong dividends offer additional safety to investors concerned about the bull market's sustainability.
  149. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  150. There's Nothing Generic About the Profits

    January 27, 2010
    Any healthcare reform will include severe cost cutting. Giving your portfolio a dose of generic-dug makers will help you ...
  151. H1N1 Vaccines Finally Bearing Revenue

    December 9, 2009
    Investors lost interest in swine flu vaccine stocks, like AZN and GSK, before they had a chance to enjoy any revenue.
  152. Four Healthcare Stocks On Fire

    November 18, 2009
    Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...
  153. Pay Attention To QLT

    October 29, 2009
    Learn how you effectively get the biopharmaceutical company for free.
  154. Long-Term Flu Plays

    October 2, 2009
    Flu vaccine shares still have long-term appeal.
  155. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  156. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  157. Are the Pros Buying? Is it Important?

    June 22, 2009
    Institutional investment numbers are not always indicative of a stock’s profit potential.
  158. Make Some $$$s From Your Lack Of ZZZs

    March 9, 2009
    If you're losing sleep over the down economy, these pharmaceutical picks might help you sleep a little easier.
  159. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
  160. Missing Forest Labs For The Trees

    October 27, 2008
    Forest Labs is facing a lull in its pipeline, but prior lulls have been good buying opportunities.
  161. 3 Strong Companies With Low P/Es

    October 24, 2008
    Fear has created many buying opportunities. We examine three companies that have low value multiples and low entry points.
  162. World Tour, Wall Street Style - France

    September 9, 2008
    From ArcelorMittal to energy giant Total, learn what investment opportunities are waiting in France.
  163. High-Risk Acquisition The Right Prescription For Pfizer?

    September 5, 2008
    Pfizer needs to refresh its pipeline, but taking on a high-risk/high-reward experimental drug could do more harm than good.
  164. Don't Let A Sciele Happen To You

    September 4, 2008
    A great idea is worth nothing if you never pull the trigger.
  165. U.S. Cancer Vaccine Gets The Green Light - In Russia

    April 11, 2008
    Russia approved U.S. biotech Antigenics' kidney cancer vaccine. The dawn of a potentially lucrative market may be at hand.
  166. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
Investing News
  1. Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First ...

    Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First Quarter ...
  2. Why Stick With Energy Stocks? (Hint: Geopolitical Risk)

    By most fundamental measures, oil prices should be declining. Russ explains why they’re on ...
  3. Bad Investor Behavior: Overemphasizing Experience

    Behavioral finance researchers have discovered that our personal experiences disproportionately ...
  4. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  5. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  6. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
Trading Center